Utility of Pan-Fungal, Aspergillus, and Mucorales PCR in the Diagnostic Evaluation of Children with Suspected Pulmonary Infections

Clicks: 64
ID: 327371
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #12 of 147 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background The incidence of pulmonary invasive fungal infections (PIFIs) in the U.S. is increasing, especially among immunocompromised populations. Traditional diagnostics have limited sensitivity/specificity and often require invasive procedures. Fungal PCRs have the potential for increasing yield and timeliness of diagnostics. This study evaluates the role of fungal PCRs in the diagnosis of PIFIs in children. Methods This retrospective cohort includes children ≤18 years with a University of Washington Pan-fungal, Aspergillus, and/or Mucorales PCR (collectively referred to as fungal PCR) sent from bronchoalveolar lavage (BAL), pleural fluid, and/or lung tissue between 01/2020-09/2025. Demographic and clinical data were collected through EPIC chart review and recorded in REDCap. The impact of fungal PCRs, as categorized by test episodes based on shared specimen source and collection date, on antifungal regimen was evaluated. Descriptive statistics were performed, and analyses were performed using R v4.4.2. Results Overall, 132 unique subjects across 150 hospitalizations were included, with a total of 171 test episodes and 302 individual fungal PCR tests. 70% of patients were immunocompromised including 40% with cancer, 36% with a transplant history, and 18% with a primary immunodeficiency. 59% of admissions involved ICU care and 19% led to a PIFI diagnosis. Only 6% (19/302) of all fungal PCRs were positive. Pan-fungal PCR was most frequently performed; 11% (18/160) were positive (Figure 1). No Aspergillus PCRs (n=116) were positive and 4% (1/26) of Mucorales PCRs were positive. PJP and Candida were the most frequently detected infections by fungal PCRs and were always concordant with traditional testing modalities such as fluorescent antibody testing and fungal culture (Figure 1). Only 4 out of 302 PCRs (1%) were positive without a concordant conventional diagnostic test, all involving molds. Following 24% of test episodes, there was a change in antifungal regimen, of which 59% credited fungal PCRs for the change. Among immunocompromised patients, there was a change in antifungal regimen following 27% of test episodes, of which 65% credited fungal PCRs. Overall, fungal PCRs were explicitly mentioned as a reason for either continuation or change in antifungals in 19% (n=33) of episodes (Table 1). Conclusion Only a minority of fungal PCR results were positive. Fungal PCR testing contributed to changes or continuation of antifungals in approximately a fifth of cases. Among immunocompromised patients, fungal PCR testing contributed to antifungal management only marginally more often. Further analysis is needed to specify in which patients this diagnostic modality is most useful.
Reference Key
openalex_W7204663997 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag070/piag070.081
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.